Suppr超能文献

骨保护素和甲状旁腺激素作为血液透析患者高转换型骨营养不良和骨矿化降低的标志物。

Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients.

作者信息

Haas Martin, Leko-Mohr Zdenka, Roschger Paul, Kletzmayr Josef, Schwarz Christoph, Domenig Christoph, Zsontsich Thomas, Klaushofer Klaus, Delling Günter, Oberbauer Rainer

机构信息

Department of Internal Medicine III, Division of Nephrology, University Vienna, Austria.

出版信息

Am J Kidney Dis. 2002 Mar;39(3):580-6. doi: 10.1053/ajkd.2002.31409.

Abstract

Osteoprotegerin (OPG) has a profound inhibitory effect on osteoclast differentiation and bone resorption. Because high-turnover renal osteodystrophy (ROD) is characterized by increased osteoclast activity, serum OPG concentrations might be used to distinguish between forms of ROD. Twenty-six patients on maintenance hemodialysis therapy underwent a transiliac crest biopsy for evaluation of histopathologic characteristics and histomorphometric studies. ROD was diagnosed as type II (normal or low turnover) or type III (high turnover plus osteoidosis) disease. Bone mineralization density distribution (BMDD) was characterized by measuring the mean trabecular calcium concentration in the biopsy specimen with quantitative backscattered electron imaging. Patients underwent additional dual-energy x-ray absorptiometry (DEXA) of the spine and hip and measurement of such biochemical markers of bone turnover as OPG, intact parathyroid hormone (iPTH), osteocalcin, calcitonin, bone alkaline phosphatase, and cross-laps. OPG levels were significantly reduced in patients with ROD III compared with ROD II (118 +/- 38 versus 204 +/- 130 pg/mL; P < 0.05) and correlated with BMDD (r = 0.43; P < 0.05). Patients with ROD III showed significantly lower BMDD compared with healthy controls (21.42% +/- 0.12% versus 22.17% +/- 0.81% weight; P < 0.01). Besides iPTH, which showed significantly greater levels in patients with ROD III than ROD II (382 +/- 322 versus 136 +/- 156 pg/mL; P < 0.05), none of the serological markers or DEXA was useful in separation of the groups. Discriminant function analysis showed that a combination of OPG and iPTH correctly classifies ROD II in 72% and ROD III in 88% of patients. We conclude that OPG in combination with iPTH can be used as a marker for noninvasive diagnosis of ROD in hemodialysis patients. Furthermore, OPG serum levels might be used to estimate trabecular bone mineralization in these subjects.

摘要

骨保护素(OPG)对破骨细胞分化和骨吸收具有显著的抑制作用。由于高转换型肾性骨营养不良(ROD)的特征是破骨细胞活性增加,血清OPG浓度可能用于区分不同类型的ROD。26例维持性血液透析治疗患者接受了髂嵴活检,以评估组织病理学特征和组织形态计量学研究。ROD被诊断为II型(正常或低转换)或III型(高转换加骨样变)疾病。通过定量背散射电子成像测量活检标本中的平均小梁钙浓度来表征骨矿化密度分布(BMDD)。患者还接受了脊柱和髋部的双能X线吸收测定(DEXA),并测量了骨转换的生化标志物,如OPG、完整甲状旁腺激素(iPTH)、骨钙素、降钙素、骨碱性磷酸酶和交联C端肽。与II型ROD患者相比,III型ROD患者的OPG水平显著降低(118±38对204±130 pg/mL;P<0.05),且与BMDD相关(r=0.43;P<0.05)。与健康对照组相比,III型ROD患者的BMDD显著降低(21.42%±0.12%对22.17%±0.81%重量;P<0.01)。除了iPTH(III型ROD患者的水平显著高于II型ROD患者,382±322对136±156 pg/mL;P<0.05)外,血清学标志物或DEXA均无助于区分两组。判别函数分析表明,OPG和iPTH的组合能正确分类72%的II型ROD患者和88%的III型ROD患者。我们得出结论,OPG与iPTH联合可作为血液透析患者ROD无创诊断的标志物。此外,OPG血清水平可用于估计这些受试者的小梁骨矿化情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验